Can pegylated interferon α 2a cause development of thyroid disorders in patients with chronic hepatitis B?

Expert Opinion on Drug Safety

Volumn 13, Issue 8, 2014, Pages 1009-1014

  Kozielewicz, Dorota ^a   Zaleśna, Agnieszka ^b   Dybowska, Dorota ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b T Browicz Provincial Infectious Diseases Hospital   (Poland)

Author keywords

Anti thyroid peroxidase antibodies; Chronic hepatitis B; Pegylated IFN ; Thyroid diseases

Indexed keywords

PEGINTERFERON ALPHA2A; THYROGLOBULIN ANTIBODY; THYROID ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; ALPHA INTERFERON; ANTIVIRUS AGENT; IODIDE PEROXIDASE; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ANTIBODY DETECTION; ARTICLE; CHRONIC HEPATITIS; DRUG EFFECT; FEMALE; FREE THYROXINE INDEX; HASHIMOTO DISEASE; HEPATITIS B; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; MAJOR CLINICAL STUDY; MALE; THYROID DISEASE; THYROIDITIS; THYROTROPIN BLOOD LEVEL; CHEMICALLY INDUCED; CLINICAL TRIAL; HEPATITIS B, CHRONIC; IMMUNOLOGY; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; INTERFERON-ALPHA; IODIDE PEROXIDASE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; THYROTROPIN; YOUNG ADULT;

EID: 84904488838     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.921156     Document Type: Article

References (19)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107
2. European Association for the Study of the Liver. 2012 EASL clinical practice guidelines:management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85
3. Pegasys-European medicines agency. 2013. Available from: Http://www.ema. europa.eu/docs/en-GB/document-library/ EPAR-Product Information/ human000395/WC500039195.pdf
4. Custro N, Montalto G, Scafidi V, et al. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J Endocrinol Invest 1997;20:374-80
5. Carella C, Mazziotti G, Amato G, et al. Interferon-A-related thyroid disease: Pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 2004;89:3656-61
6. Mandac JC, Chaundhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-Alfa induced thyroiditis: Toward a new classification. Hepatology 2006;43:661-72
7. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha 2 a. Eur J Endocrinol 1995;132:587-93
8. Costelloe S, Wassef N, Schulz J, et al. Thyroid dysfunction in a UK hepatitis C population treated with interferon-A and ribavirin combination therapy. Clin Endocrinol (Oxf) 2010;73:249-56
9. Chen XF, Chen XP, Ma XJ, et al. Prevalence and clinical characteristics of thyroid disease induced by chronic hepatitis B treated with polyethylene glycol (peg) interferon-Alfa [Article in Chinese]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2012;26:117-19
10. Kartal ED, Alpat SN, Ozgunes I, Usluer G. Adverse effects of high-dose interferon-A-2a treatment for chronic hepatitis B. Adv Ther 2007;24:963-71
11. Kaymakoglu S, Oguz D, Gur G, et al. Pegylated interferon alfa 2b monotherapy and pegylated interferon alfa 2b plus lamivudine combination therapy for patient with hepatitis B virus e antigen negative chronic hepatitis B. Antimicrob Agents Chemother 2007;51:3020-2
12. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon Alfa-2a HBeAg-negative chronic hepatitis B study group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17
13. Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a HBeAg-positive chronic hepatitis B study group. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95
14. Kek PC, Ho SC, Khoo DH. Subclinical thyroid disease. Singapore Med J 2003;44:595-600
15. Caraccio N, Giannini R, Cuccato S, et al. Type I interferons modulate the expression of thyroid peroxidase, sodium/ iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J Clin Endocrinol Metab 2005;90:1156-62
16. Kee KM, Lee CM, Wang JH, et al. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: Incidence, associated factors and prognosis. J Gastroenterol Hepatol 2006;21:319-26
17. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 1998;158:1445-8
18. Devdhar Y, Ousman YH, Burman KD. Hypothyroidism. Endocrinol Metab Clin North Am 2007;36:595-615
19. Nayak B, Hodak SP. Hyperthyroidism. Endocrinol Metab Clin North Am 2007;36:617-56